MERTK receptor tyrosine kinase is a therapeutic target in melanoma

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2257-2267

  Schlegel, Jennifer ^a   Sambade, Maria J ^b   Sather, Susan ^a   Moschos, Stergios J ^b,c   Tan, Aik Choon ^d   Winges, Amanda ^a   DeRyckere, Deborah ^a   Carson, Craig C ^c   Trembath, Dimitri G ^c   Tentler, John J ^d   Eckhardt, S Gail ^d   Kuan, Pei Fen ^b,e   Hamilton, Ronald L ^f   Duncan, Lyn M ^g   Miller, C Ryan ^b,c   Nikolaishvili Feinberg, Nana ^b   Midkiff, Bentley R ^c   Liu, Jing ^c,h   Zhang, Weihe ^c,h   Yang, Chao ⁱ   Wang, Xiaodong ^c,h   Frye, Stephen V ^b,c,h   Earp, H Shelton ^b   Shields, Janiel M ^b,c   Graham, Douglas K ^a   more..

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e University of North Carolina at Chapel Hill   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNC Hamner Institute for Drug Safety Sciences   (United States)

ⁱ Anichem   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C MER PROTO ONCOGENE TYROSINE KINASE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SHORT HAIRPIN RNA; STAT PROTEIN; UNC 1062; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOCYTES; MELANOMA; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; MUTATION; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SKIN NEOPLASMS;

EID: 84877114887     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67816     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
3. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
4. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346.
5. Nazarian R, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
6. Johannessen CM, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-972.
7. Atefi M et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973.
8. Poulikakos PI, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387-390.
9. Shi H, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012;3:724.
10. Graham DK, et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006;12(9):2662-2669.
11. Linger RMA, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer [published online ahead of print August 13, 2012]. Oncogene. doi:10.1038/onc.2012.355.
12. Wu Y-M, Robinson DR, Kung H-J. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res. 2004;64(20):7311-7320.
13. Keating AK, et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther. 2010;9(5):1298-1307.
14. Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35-83.
15. Rogers AEJ, et al. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene. 2011;31(38):4171-4181.
16. Tworkoski K, et al. Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res. 2011;9(6):801-812.
17. Zhu S, et al. A genomic screen identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci USA. 2009;106(40):17025-17030.
18. Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011;131(12):2448-2457.
19. Nazarian RM, Prieto VG, Elder DE, Duncan LM. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 2010;37:41-47.
20. Scott RS, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature. 2001;411(6834):207-211.
21. Riker AI, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics. 2008;1(1):13.
22. Wellbrock C, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004;64(7):2338-2342.
23. Migdall-Wilson J, et al. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One. 2012;7(2):e31635.
24. Sather S, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109(3):1026-1033.
25. Lee J-H, Choi J-W, Kim Y-S. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776-784.
26. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851-857.
27. Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006;355(1):51-65.
28. Dutton-Regester K, Hayward NK. Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res. 2012;25(2):144-154.
29. Liu J, et al. Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia. ACS Med Chem Lett. 2012;3(2):129-134.
30. Sambade MJ, et al. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol. 2011;98(3):394-399.
31. Hodis E, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251-263.
32. Gustafsson A, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009;15(14):4742-4749.
33. Gogas H, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709-718.
34. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8(11):1323-1327.
35. Barrett T et al. NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res. 2011;39(Database issue):D1005-D1010.
36. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
37. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
38. Carson C, et al. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines. Pigment Cell Melanoma Res. 2012;25(4):514-526.
39. Wang X, Liu J, Yang C, Zhang W, Frye S, Kireev D, inventors; The University of North Carolina at Chapel Hill, assignee. Pyrazolopyrimidine compounds for the treatment of cancer. US patent WO/2011/146313. November 24, 2011.